| Immune dysfunction in cirrhosis N Sipeki, P Antal-Szalmas, PL Lakatos, M Papp World journal of gastroenterology: WJG 20 (10), 2564, 2014 | 192 | 2014 |
| Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn’s patients: the importance of specific target … M Papp, N Sipeki, T Tornai, I Altorjay, GL Norman, Z Shums, ... Journal of Crohn's and Colitis 9 (8), 659-668, 2015 | 55 | 2015 |
| High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis M Papp, N Sipeki, Z Vitalis, T Tornai, I Altorjay, I Tornai, M Udvardy, ... Journal of hepatology 59 (3), 457-466, 2013 | 49 | 2013 |
| Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 months S Pape, TJG Gevers, JM Vrolijk, B van Hoek, G Bouma, ... Clinical gastroenterology and hepatology 18 (7), 1609-1617. e4, 2020 | 40 | 2020 |
| Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients G Kovacs, N Sipeki, B Suga, T Tornai, K Fechner, GL Norman, Z Shums, ... PLoS One 13 (3), e0194166, 2018 | 30 | 2018 |
| Macrophage activation marker, soluble CD 163, is an independent predictor of short‐term mortality in patients with cirrhosis and bacterial infection T Tornai, Z Vitalis, N Sipeki, T Dinya, D Tornai, P Antal‐Szalmas, ... Liver International 36 (11), 1628-1638, 2016 | 30 | 2016 |
| Identification of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease C Deutschmann, M Sowa, J Murugaiyan, U Roesler, N Röber, K Conrad, ... Journal of Crohn's and Colitis 13 (7), 894-904, 2019 | 29 | 2019 |
| Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease N Sipeki, L Davida, E Palyu, I Altorjay, J Harsfalvi, PA Szalmas, Z Szabo, ... World journal of gastroenterology: WJG 21 (22), 6952, 2015 | 28 | 2015 |
| Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis T Tornai, D Tornai, N Sipeki, I Tornai, R Alsulaimani, K Fechner, ... Scientific reports 8 (1), 399, 2018 | 27 | 2018 |
| Lectin‐complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections I Foldi, T Tornai, D Tornai, N Sipeki, Z Vitalis, I Tornai, T Dinya, ... Liver International 37 (7), 1023-1031, 2017 | 25 | 2017 |
| High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation S Pape, TJG Gevers, JM Vrolijk, B van Hoek, G Bouma, ... Liver international 40 (9), 2164-2171, 2020 | 22 | 2020 |
| Major changes of von Willebrand factor multimer distribution in cirrhotic patients with stable disease or acute decompensation E Palyu, J Harsfalvi, T Tornai, M Papp, M Udvardy, K Szekeres-Csiki, ... Thrombosis and Haemostasis 118 (08), 1397-1408, 2018 | 22 | 2018 |
| Risk matrix for prediction of disease progression in a referral cohort of patients with Crohn’s disease PL Lakatos, N Sipeki, G Kovacs, E Palyu, GL Norman, Z Shums, ... Journal of Crohn's and Colitis 9 (10), 891-898, 2015 | 14 | 2015 |
| Abnormal ferritin levels predict development of poor outcomes in cirrhotic outpatients: a cohort study D Tornai, P Antal-Szalmas, T Tornai, M Papp, I Tornai, N Sipeki, T Janka, ... BMC gastroenterology 21, 1-13, 2021 | 9 | 2021 |
| Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality D Tornai, Z Vitalis, A Jonas, T Janka, I Foldi, T Tornai, N Sipeki, A Csillag, ... Clinics and Research in Hepatology and Gastroenterology 45 (5), 101579, 2021 | 8 | 2021 |
| Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: computer-aided versus conventional microscopic evaluation of routine diagnostic samples from … G Nagy, I Csípő, T Tarr, G Szűcs, A Szántó, T Bubán, N Sipeki, ... Clinica Chimica Acta 511, 117-124, 2020 | 6 | 2020 |
| P288 Gut barrier failure biomarkers in IBD: Is there anything new beyond „The Wall’? N Sipeki, P Kovats, B Balogh, Z Shums, GL Norman, P Antal-Szalmas, ... Journal of Crohn's and Colitis 14 (Supplement_1), S296-S296, 2020 | 1 | 2020 |
| Identification of Chitinase-3-Like Protein 1 as a Novel Neutrophil Antigenic Target in Crohn’s U Roesler, N Röber, K Conrad, MW Laass, D Bogdanos, N Sipeki, ... J Crohns Colitis 894, 904, 2019 | 1 | 2019 |
| P152 Reconsidering the prognostic value of traditional serologic antibodies in Crohn's disease–immunoglobulin classes to take the centre stage N Sipeki, GL Norman, Z Shums, G Veres, PL Lakatos, P Antal-Szalmas, ... Journal of Crohn's and Colitis 11 (suppl_1), S153-S154, 2017 | 1 | 2017 |
| Sa1156 Accelerated Treatment Strategy in Inflammatory Bowel Diseases; Is It Associated With a Change in the Disease Course? PA Golovics, K Farkas, N Sipeki, Z Kurti, M Rutka, LS Kiss, BD Lovasz, ... Gastroenterology 148 (4), S-242-S-243, 2015 | 1 | 2015 |
